Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation - 4-Year experience at a moderate-volume center

Pediatric Transplantation

Volumn 7, Issue 2, 2003, Pages 119-124

  Jensen, Sena ^a   Jackson, Elizabeth Connor ^a   Riley, Lena ^a   Reddy, Sudhakar ^a   Goebel, Jens ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Kidney; Pediatric; Steroid; Tacrolimus; Transplantation; Withdrawal

Indexed keywords

CORTICOSTEROID; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; AVASCULAR NECROSIS; CANDIDIASIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE INTOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MYCOSIS; PRESCHOOL CHILD; SCHOOL CHILD;

ADOLESCENT; CHILD; CLINICAL PROTOCOLS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0037396960     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00027.x     Document Type: Article

References (22)

1. SEIKALY M, HO PL (Martin), EMMETT L, TEJANI A. The 12th annual report of the North American pediatric renal transplant cooperative study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001: 5: 215-231.
2. KASISKE BL, VASQUEZ MA, HARMON WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000: 11: S1-S86.
3. TÖNSHOFf B, HAFENER D, MEHLS O, et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney International 1993: 44: 199-207.
4. PIRSCH JD, MILLER J, DEIERHOI MH, VINCENTI F, FILO RS for the FK506 Kidney Translplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977-983.
5. MAYER DA, DMITREWSKI J, SQUIFFLRT J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 64: 436-443.
6. SCHNECK FX, JORDAN ML, JENSEN CWB. et al. Pediatric renal transplantation under FK-506 immunosuppression. J Urology 1992: 147: 1585-1587.
7. SHAPIRO R, SCANTLEBURY VP, JORDAN ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999: 67: 299-303.
8. REISMAN L, LIEBERMAN KV, BURROWS L, SCHANZER H. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation Of prednisone. Transplantation 1990: 49: 76-80.
9. CHAO SM, JONES CL, POWELL HR, et al. Triple immunosuppression with subsequent prednisolone withdrawal: 6 years' experience in paediatric renal allograft recipients. Pediatr Nephrol 1994: 8: 62-69.
10. MONIER-FAUGERE M-C, MAWAD H, QI Q, FRIEDLER RM. MALLUCHE H. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000: 11: 1093-1099.
11. FEBER J, BRAILLON P, DAVID L, COCHAT P. Body composition in children after renal transplantation. Am J Kidney Disease 2001: 38: 366-370.
12. MILLER BW, BRENNAN DC. Withdrawal or avoidabce of corticosteroids after renal transplantation. Up To Date 2001, http://transplantation.medscape.com.
13. HAMIWKA L, GIRARDIN C, BURNS A, DROLET D, TOM A, BELL LE. Prednisone withdrawal in pediatric renal transplant recipients: follow-up data beyond 18 months. Am J Transplantation (abstract no. 471) 2002: 2: 256.
14. SHERBOTIE J, SMITH L, TERRILL C, SOMERVILLE T, HOLMAN J. Steroid minimization in living donor pediatric renal transplantation. Am J Transplantation (abstract no. 222) 2002: 2: 194.
15. ISHITANI M, ISAACS R, NORWOOD V, NOCK S, LOBO P. Predictors of Graft Survival in Pediatric Living-Related Kidney Transplant Recipients. Transplantation 2000: 70: 288-292.
16. LIGHTENBERG G, HENÉ RJ, BLANKENSTIJN PJ, KOOMANS HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001: 12: 368-373.
17. RUSH DN, NICKERSON P, JEFFERY JR, MCKENNA RM, GRIMM PC, GOUGH J. Protocol biopsies in renal transplantation: research tool or clinically useful? Current Opinion in Nephrology and Hypertension 1998: 7: 691-694.
18. GLOOR JM, COHEN AJ, LAGER DJ, et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002: 73: 1965-1968.
19. ROTH D, COLONA J, BURKE GW, CIANCIO G, ESQUENAZI V, MILLER J. Primary immunosuppression with tacrolimus and mycophenolate mofetil ror renal allograft recipients. Transplantation 1998: 65: 248-252.
20. BUTANI L, PALMER J, BALUARTE HJ, POLINSKY MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999: 68: 83-86.
21. MCKEE M, SEGEV D, WISE B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Ped Surgery 1997: 32: 688-690.
22. SARWAL MM, YORGIN PD, ALEXANDER S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001: 72: 13-21.